Pharma & Biotech Global Week in Review 30 March 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Australia: Surprise! New pharmaceutical compulsory licenses proposed for patented medicines (Patentology) (ipwars)

Perindopril – UK: EWHC (Pat): Cross-undertakings and ex turpi causa: Servier v Apotex (IPKat) (IP finance)

Taxotere (Docetaxel) – US: CAFC issues warning on improper cross appeals: Aventis v Hospira (Patently-O) (IPBiz)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Pharmaceutical, biotechnology and chemical inventions – world protection and exploitation (FDA Law Blog)

Gene patents on the high seas: who owns the ocean’s IP? (Ars Technica)

Call issued for UN intervention in trans-pacific regional trade pact (IP Watch)

Committee nears final review of WHO performance on H1N1 pandemic (IP Watch)

Big losses loom for big pharma (IP Osgoode)

Australia: ‘Late’ submissions to Senate inquiry on ‘gene patent’ ban (Patentology)

Australia: Surprise! New pharmaceutical compulsory licenses proposed for patented medicines (Patentology) (ipwars)

Canada: Election drum beats the life out of Access to Medicines Bill (IP Osgoode)

EU opines on the patentability of human embryonic stem cells: Brüstle v Greenpeace (Kluwer Patent Blog) (IPBiz)

EU: In the ECJ this week: Case C-195/09 Synthon v Merz Pharma and Case C-427/09 Generics (UK) v Synaptech (The SPC Blog)

India: The production of generic drugs in India: A new trade agreement with the EU would hinder access to drugs in developing countries (Knowledge Ecology International)

India: International Conference concludes TKDL can prevent misappropriation and fuel innovation (WIPO) (IP Watch)

Israel: Alexandria – Health Science; not health related nor scientific, but so what? (The IP Factor)

Products

Actonel (Risedronate) – US: Warner Chilcott files patent infringement complaint against Mylan in response to Para IV certification (Patent Docs)

Actos (Pioglitazone) – US: Takeda files patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Antara (Fenofibrate) – US: Lupin files patent infringement lawsuits against Mylan, Apotex following Para IV certification (Patent Docs)

Drospirenone, Ethinylestradiol – EU: Inventive step, obvious-to-try and hindsight: Gedeon Richter plc v Bayer Schering Pharma AG (PatLit)

Eloxatin (Oxaliplatin) – US: CAFC notes that ‘legal argument’ should not be deemed confidential: In re violation of rule 28(D) (IPBiz)

Escitalopram – Denmark: More on Escitalopram PI cases in Denmark (Kluwer Patent Blog)

Finasteride – France: Tribunal de Grande Instance Paris: Dosage regime excluded from patentability: Actavis v. Merck (Kluwer Patent Blog)

Keppra (Levetiracetam) – US: Orange Book patent listing precipitates DJ action to trigger generic Keppra XR 180-day exclusivity forfeiture: Par Pharmaceutical v UCB et al (FDA Law Blog) (Patent Docs)

Naropin (Ropivacaine) – US: Judge O’Malley in dissent: Patent assignments should be a matter of state law: Abraxis BioScience v. Navinta (Patently-O)

NuvaRing (Etonogestrel, Ethinyl estradiol) – US: ITC institutes investigation (337-TA-768) regarding Certain Vaginal Ring Birth Control Devices (ITC 337 Law Blog)

Nuvigil (Armodafinil) – US: Cephalon drops patent suit against Actavis over Nuvigil generic (Patent Docs)

Oxycontin (Oxycodone) – US: Purdue Pharma files patent infringement suit against Watson in response to Para IV certification filing (Patent Docs)

Perindopril – UK: EWHC (Pat): Cross-undertakings and ex turpi causa: Servier v Apotex (IPKat) (IP finance)

Pravastatine – France: No saisie-contrefaçon after the expiry of the intellectual property right? (Kluwer Patent Blog)

Prezista (Darunavir) – US: Tibotec files patent infringement complaint against Teva in response to Para IV certification (Patent Docs)

Provigil (Modafinil) – US: Apotex’s generic Provigil found not to infringe Cephalon patent (Patent Docs)

Seasonique (Levonorgestrel, Ethinyl estradiol) – US: CAFC reversed summary judgment of nonobviousness in Duramed v Watson (Patent Docs) (IPBiz)

Simcor (Niacin/Simvastatin) – US: Abbott files patent infringement complaint against Teva in response to Para IV certification (Patent Docs)

Solaraze (Diclofenac) – US: Nycomed files for declaratory judgment of noninfringement against Glycobiosciences based on manufacture and sale of Solaraze (Patent Docs)

Tarceva (Erlotinib) – US: OSI, Genentech and Pfizer settle Tarceva patent litigation with Teva (Patent Docs)

Taxotere (Docetaxel) – US: CAFC issues warning on improper cross appeals: Aventis v Hospira (Patently-O) (IPBiz)

Valsartan, Hydrochlorothiazide – Germany: Update on Novartis v Actavis in Düsseldorf (The SPC Blog) (EPLAW)

Zicam (Zinc gluconate) – US: Supreme Court increases disclosure burdens on pharma companies: Matrixx v Siracusano (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: